Latest Tax Incentives News

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Pivotal Metals highlights its fully funded exploration programs targeting high-grade copper and gold deposits in Quebec, underpinned by a significant pit-constrained resource and strategic advantages in a tier 1 jurisdiction.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Kingsgate Consolidated Limited reported record quarterly gold and silver production at its Chatree Gold Mine, alongside strong cash growth and strategic project advances in its November 2025 AGM update.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Elixir Energy has raised approximately AUD 16.6 million through a two-tranche placement led by Omega Oil & Gas, aiming to fast-track its Taroom Trough gas projects and advance toward commercial production.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.